What exactly did BMO change for Regeneron on Feb 02, 2026?

BMO Capital **maintained** its **Outperform** rating on Feb 02, 2026. The firm reaffirmed confidence in Regeneron’s commercial momentum but did not issue a new price target in the StreetInsider note.

How should investors interpret this REGN analyst rating?

A maintained Outperform signals continued analyst confidence and suggests potential upside. Investors should compare the rating with other price targets and watch upcoming revenue and pipeline catalysts before trading.

Did the BMO note move REGN shares?

The note coincided with a modest market reaction of **-0.57%** or **$-4.31**, indicating the update was largely expected by the market and did not trigger a major re-rate.

Where can I find related analyst changes and price targets for REGN?

Track analyst actions on financial news sites and the Meyka REGN stock page. Recent coverage includes Baird’s target change reported on Investing.com [source](https://www.investing.com/news/analyst-ratings/td-).

Analyst Ratings

Feb 02, 2026 BMO Maintains Outperform on REGN (Regeneron Pharmaceuticals, Inc.)

ByDanny Kontos February 3, 2026February 3, 2026

BMO Capital maintained an Outperform rating on Regeneron Pharmaceuticals, Inc. (REGN) on Feb 02, 2026. This REGN analyst rating signals BMO’s view that commercial momentum sets up 2026 and supports revenue upside. The action was recorded at 09:25 AM and accompanied a small share move of -0.57% (down $-4.31). Investors should treat this as confirmation of prior conviction, not a new upgrade or downgrade, and read the analyst commentary for product-specific catalysts.